My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1625

    1.

    Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.

    Juhl CB, Pørksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O.

    Diabetes. 2001 Aug;50(8):1778-84.PMID: 11473038 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.

    Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, Pørksen N, Schmitz O, Juhl CB.

    Diabet Med. 2005 Oct;22(10):1408-13.PMID: 16176204 [PubMed - indexed for MEDLINE]Related articles

    3.

    Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.

    Juhl CB, Pørksen N, Hollingdal M, Sturis J, Pincus S, Veldhuis JD, Dejgaard A, Schmitz O.

    Diabetes Care. 2000 May;23(5):675-81.PMID: 10834429 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.

    Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.

    Diabetes. 2001 Apr;50(4):776-84.PMID: 11289042 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Short-term treatment with GLP-1 increases pulsatile insulin secretion in Type II diabetes with no effect on orderliness.

    Juhl CB, Schmitz O, Pincus S, Holst JJ, Veldhuis J, Pørksen N.

    Diabetologia. 2000 May;43(5):583-8.PMID: 10855533 [PubMed - indexed for MEDLINE]Related articles

    6.

    Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

    Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

    Diabetes. 2002 Feb;51(2):424-9.PMID: 11812750 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

    Roberts VL, Stewart J, Issa M, Lake B, Melis R.

    Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

    8.

    Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.

    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.

    Clin Ther. 2007 Nov;29(11):2349-64.PMID: 18158076 [PubMed - indexed for MEDLINE]Related articles

    9.

    Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

    Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.

    Diabetes. 1998 Jan;47(1):45-9.PMID: 9421373 [PubMed - indexed for MEDLINE]Related articles

    10.

    Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans.

    Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Pørksen N.

    Diabetologia. 2002 Jan;45(1):49-55.PMID: 11845223 [PubMed - indexed for MEDLINE]Related articles

    11.

    Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus.

    Ligtenberg JJ, Reitsma WD, van Haeften TW.

    Horm Metab Res. 2001 Jun;33(6):361-4.PMID: 11456286 [PubMed - indexed for MEDLINE]Related articles

    12.

    Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.

    van der Wal PS, Draeger KE, van Iperen AM, Martini C, Aarsen M, Heine RJ.

    Diabet Med. 1997 Jul;14(7):556-63.PMID: 9223393 [PubMed - indexed for MEDLINE]Related articles

    13.

    Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

    Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

    Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

    14.

    Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.

    Chow CC, Tsang LW, Sorensen JP, Cockram CS.

    Diabetes Care. 1995 Mar;18(3):307-14.PMID: 7555472 [PubMed - indexed for MEDLINE]Related articles

    15.

    A double-masked placebo-controlled trial assessing effects of various doses of BTS 67,582, a novel insulinotropic agent, on fasting hyperglycemia in NIDDM patients.

    Skillman CA, Raskin P.

    Diabetes Care. 1997 Apr;20(4):591-6.PMID: 9096985 [PubMed - indexed for MEDLINE]Related articles

    16.

    Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

    Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

    Diabet Med. 1998 Nov;15(11):937-45.PMID: 9827848 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.

    Clark HE, Matthews DR.

    Horm Metab Res. 1996 Sep;28(9):445-50.PMID: 8911981 [PubMed - indexed for MEDLINE]Related articles

    18.

    A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

    Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

    Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

    19.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.

    Carroll MF, Izard A, Riboni K, Burge MR, Schade DS.

    Diabetes Care. 2002 Dec;25(12):2147-52.PMID: 12453952 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity